175 related articles for article (PubMed ID: 21447877)
1. HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies.
Mascolini M; Mellors JW; Richman DD; Boucher CA; Larder BA
Antivir Ther; 2011; 16(2):263-86. PubMed ID: 21447877
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
Buti M
IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
[No Abstract] [Full Text] [Related]
3. Antiviral research--21st international conference.
Turner B
IDrugs; 2008 Jun; 11(6):401-4. PubMed ID: 18509777
[No Abstract] [Full Text] [Related]
4. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
Masgala A; Bonovas S; Nikolopoulos GK
Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of drug resistance in hepatitis viruses B and C].
Yotsuyanagi H; Koike K
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():493-6. PubMed ID: 17455669
[No Abstract] [Full Text] [Related]
6. Primary infection with a lamivudine-resistant hepatitis B virus.
Thibault V; Aubron-Olivier C; Agut H; Katlama C
AIDS; 2002 Jan; 16(1):131-3. PubMed ID: 11741175
[No Abstract] [Full Text] [Related]
7. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.
Mascolini M; Richman D; Larder B; Mellors J; Boucher CA
Antivir Ther; 2008; 13(2):319-34. PubMed ID: 18505183
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antiviral resistance across acute and chronic viral infections.
Mason S; Devincenzo JP; Toovey S; Wu JZ; Whitley RJ
Antiviral Res; 2018 Oct; 158():103-112. PubMed ID: 30086337
[TBL] [Abstract][Full Text] [Related]
10. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Soriano V; Perelson AS; Zoulim F
J Antimicrob Chemother; 2008 Jul; 62(1):1-4. PubMed ID: 18441341
[TBL] [Abstract][Full Text] [Related]
11. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
12. Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.
Mascolini M; Boucher CA; Mellors JW; Larder BA; Richman DD
Antivir Ther; 2009; 14(7):1015-37. PubMed ID: 19918107
[TBL] [Abstract][Full Text] [Related]
13. Designing a low-cost drug resistance database for viral hepatitis.
Kuiken C
Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant viral hepatitis.
Wright M; Main J; Thomas HC
J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
[No Abstract] [Full Text] [Related]
15. Virology of hepatitis B and C viruses and antiviral targets.
Pawlotsky JM
J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
[TBL] [Abstract][Full Text] [Related]
16. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.
Götte M
Curr Opin Virol; 2012 Oct; 2(5):644-50. PubMed ID: 22964133
[TBL] [Abstract][Full Text] [Related]
17. Cell-based and animal models for hepatitis B and C viruses.
Schinazi RF; Ilan E; Black PL; Yao X; Dagan S
Antivir Chem Chemother; 1999 May; 10(3):99-114. PubMed ID: 10431609
[TBL] [Abstract][Full Text] [Related]
18. Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008.
Haubrich R; Soriano V; Lafeuillade A
HIV Clin Trials; 2008; 9(5):348-65. PubMed ID: 18977724
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of HIV and viral hepatitis by analysis of samples from drug related deaths.
Christensen PB; Kringsholm B; Banner J; Thomsen JL; Cowan S; Stein GF; Jürgensen GW; Grasaasen K; Georgsen J; Pedersen C
Eur J Epidemiol; 2006; 21(5):383-7. PubMed ID: 16763882
[TBL] [Abstract][Full Text] [Related]
20. Low-abundance drug resistance mutations: extending the HIV paradigm to hepatitis B virus.
Menzo S; Vincenti D; Solmone M; Prosperi M; Bruselles A; Abbate I; Rozera G; Capobianchi MR
J Infect Dis; 2009 Dec; 200(11):1798-9; author reply 1799-1800. PubMed ID: 19905934
[No Abstract] [Full Text] [Related]
[Next] [New Search]
